NYSEMKT: NNVCNanoviricides Inc Stock
$1.18+0.02 (+1.72%)
Updated Apr 18, 2024
NNVC Price
$1.18
Fair Value Price
N/A
Market Cap
$13.84M
52 Week Low
$1.00
52 Week High
$2.00
P/E
-1.45x
P/B
1.11x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$6M
Beta
0.06
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NNVC Overview
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 17 full-time employees. The firm is a development-stage company with several drugs in various stages of development. The firm focuses on its research and clinical programs on specific anti-viral therapeutics. The firm is engaged in the application of nanomedicine technologies to the issues of viral diseases. The firm's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NNVC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NNVC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NNVC is good value based on its book value relative to its share price (1.11x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
NNVC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NNVC due diligence checks available for Premium users.
Be the first to know about important NNVC news, forecast changes, insider trades & much more!
NNVC News
Valuation
NNVC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.45x
Industry
15.68x
Market
41.33x
NNVC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.11x
Industry
5.76x
NNVC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NNVC's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
NNVC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.4M
Liabilities
$951.1k
Debt to equity
0.08
NNVC's short-term assets ($5.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NNVC's short-term assets ($5.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NNVC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NNVC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
-$5.5k
Financing
$0.0
NNVC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NNVC vs Biotech Stocks
Nanoviricides Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.